Publications by authors named "Lorna M Torres"
Article Synopsis
- The study aimed to determine if selecting oral antiplatelet drugs based on a patient's genotype using a clinical decision support algorithm can lower the rate of major adverse cardiovascular and cerebrovascular events among Caribbean Hispanic patients following treatment.
- Conducted as an open-label, multicenter, non-randomized trial across eight hospitals in Puerto Rico, it involved 300 patients who received percutaneous coronary intervention and were divided into standard-of-care and genotype-guided groups.
- Results indicated that although the genotype-guided group had a lower risk of major adverse events compared to the standard group (8.7% vs 10.7%), the difference was not statistically significant.
Background: After percutaneous coronary intervention (PCI), clopidogrel resistant patients are at an increased risk of major adverse cardiovascular and cerebrovascular events (MACCEs). We aimed to assess whether genotype-guided selection of oral antiplatelet drugs using a clinical decision support (CDS) algorithm reduces the occurrence of these ischemic events and improves outcomes among Caribbean Hispanic patients from Puerto Rico, who are underrepresented in clinical pharmacogenomic (PGx)-guided implementation studies.
Methods: Individual platelet function testing (PRU) measures, *2 and rs662 genotypes, clinical and demographic data from 8 medical facilities were included.